Abstract: The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.

Abstract: The novel process for preparing dialkyl dicarbonates by reacting the corresponding alkyl haloformates with alkali metal hydroxides, alkaline earth metal hydroxides and/or carbonates in the presence of water-immiscible organic solvents and in the presence of a catalyst is characterized in that the catalyst used is at least one tertiary alkylamine of the formula (I) NR1R2R3,??(I) where the substituents are each as defined in the description.

Abstract: Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, 0, P, Q, T, U, V, Y, ?, ?, ?, ?, ?, ?, ? and ?, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.

Abstract: Disclosed is an optimized system for more efficiently and economically producing terephthalic acid. The system includes an optimized post-digestion cooling stage that provides a TPA product having enhanced purity, while minimizing costs associated with removing impurities from recycled solvent.

Abstract: A novel process for the preparation of tolterodine, i.e. (R)—N, N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, in the racemic form, as well as intermediates useful for its preparation.

Abstract: The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target.

Abstract: Process for the hydroformylation of an optionally substituted ethylenically unsaturated compound by reaction thereof with carbon monoxide and hydrogen in the presence of a specific catalyst system which includes a source of Group VIII metal cations; a diphosphine ligand having the general formula (I): X1—R—X2 ??(I) wherein X1 and X2 each independently represent an optionally substituted cyclic group with at least 5 ring atoms, of which one is a phosphorus atom, and R represents a bivalent optionally substituted bridging group which is connected to each phosphorus atom by a sp2 hybridized carbon atom; an acid having a pKa<3; and a source of halide anions.

Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound.

Abstract: The invention relates to a method for producing glycerol carbonate methacrylate in the presence of metal-chelate catalysts of the metal ion-1,3-diketonate type.

Abstract: The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with anti-inflammatory activity due to inhibition of cyclooxygenase enzymes.

Abstract: The invention pertains to a method for the production of raw materials for candle production and for heat storage material, such as waxes, in which from a starting material containing lipids, the lipids are extracted and/or refined and/or hydrogenated. As the starting material, a mixture of organic materials containing lipids, in particular mixtures of food residues, old cooking fats and/or recycled food materials from the food industry, and/or animal fats are washed and comminuted, in a first method step; in a second method step, the lipids are isolated; and next, the lipids are selectively esterified and/or refined and/or hydrogenated into the raw material for the candle production or for the heat storage material.

Abstract: There is provided stereoselective route to a compound of formula I: wherein R represents H or an alkali metal, Ar1 represents 4-chlorophenyl and Ar2 represents 2,5-difluorophenyl.

Abstract: The present invention relates to a method of preparing a phenoxy alkanoic, alkenoic, or alkynoic acid or a salt thereof from a phenoxy containing compound via a dicarboxylate intermediate. The phenoxy alkanoic, alkenoic, and alkynoic acids and salts thereof prepared by this method are suitable for use in composition for delivering active agents via oral or other routes of administration to animals. Furthermore, the present invention relates to phenoxy dicarboxylic acids and their salts for delivering active agents, such as biologically or chemically active agents, to a target.

Abstract: The present invention is to provide a method of producing an N-alkylaminoalkyl (meth)acrylate containing a small amount of low boiling components, especially, containing a small amount of raw components, without any complicated operations or special apparatuses. The method of producing an N-alkylaminoalkyl (meth)acrylate comprising the steps of: (A) performing the reaction between the (meth)acrylic acid ester and the N-alkylaminoalkyl alcohol in a presence of a catalyst to obtain a reaction solution containing the N-alkylaminoalkyl (meth)acrylate; (B) distilling out components which have lower boiling points than the N-alkylaminoalkyl (meth)acrylate from the reaction solution obtained by the step (A); and (C) distilling the N-alkylaminoalkyl (meth)acrylate; and further comprising the step of: (D) adjusting water concentration at a range from 0.01 to 1 wt %. in the reaction solution which is located after the step (A) and before the step (C).

Abstract: A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the following general formula (I): wherein X represents a single bond or a C1 to C6 alkylene group which may be substituted; A represents a C1 to C6 alkyl group which may be substituted, a C6 to C10 aryl group which may be substituted, or a 4 to 10-membered monocyclic or bicyclic and unsaturated, partly saturated, or completely saturated heterocyclic group which may be substituted, wherein said heterocyclic group comprises as ring-constituting atoms 1 to 4 hetero atoms selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom.

Abstract: The invention relates to a process for treating an aqueous medium containing cyclohexanone oxime and cyclohexanone, said process comprising stripping the aqueous medium with steam, wherein said stripping is carried out at a pressure higher than 0.11 MPa. The invention also relates to a process for the preparation of cyclohexanone oxime, which involves stripping at a pressure higher than 0.11 MPa.

Abstract: A compound of formula (I) or formula (II) wherein the variables are as defined in the claims

Abstract: The present invention provides pharmaceutical compositions useful in treating hepatitis C infection. The present invention also provides methods of treating hepatitis C infection by administering to a mammal the pharmaceutical compositions of the present invention.

Abstract: Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

Abstract: The present invention provides new microreactor systems, catalysts, and chemical processes. Methods of making novel catalysts and reaction apparatus are also described.